Cleerly ISCHEMIA vs Libby Echo:Prio

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Cleerly
VS
by Dyad Medical

AI Verdict

Cleerly ISCHEMIA focuses on analyzing CCTA scans to assess coronary artery ischemia and plaque, aiding in the diagnosis of coronary artery disease. In contrast, Libby Echo:Prio specializes in echocardiogram analysis for cardiac function quantification and automated measurements. While both are cardiology AI tools, they address distinct diagnostic needs using different imaging modalities.

Choose Cleerly ISCHEMIA if…

Choose Cleerly ISCHEMIA if you require a comprehensive, non-invasive assessment of coronary artery disease and vessel-level ischemia using CCTA scans. This tool is ideal for detailed plaque characterization, stenosis severity assessment, and non-invasive fractional flow reserve estimation to guide personalized diagnosis and treatment planning for heart disease.

View Cleerly ISCHEMIA →

Choose Libby Echo:Prio if…

Choose Libby Echo:Prio if your primary need is fast, automated, and consistent quantification of cardiac function and measurements from echocardiograms. This cloud-based platform is particularly well-suited for providing immediate decision support and a reliable second opinion in settings where remote access and efficient workflow integration are critical.

View Libby Echo:Prio →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Cleerly ISCHEMIA Libby Echo:Prio
Pricing Unknown Custom
Deployment Web-based solution Cloud-based
BAA Available Yes AI-estimated No AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated No AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Libby Echo:Prio

Libby Echo:Prio emphasizes a cloud-based platform with remote access from any device and seamless embedding into existing clinical workflows, suggesting a highly accessible and integrated user experience. While Cleerly ISCHEMIA also offers a web-based platform and PowerScribe integration, its data transfer via Cleerly Proxy and the need for IT integration support might introduce slightly more complexity in initial setup compared to a purely cloud-native solution.

Clinical Value

Cleerly ISCHEMIA

Cleerly ISCHEMIA provides a more comprehensive and predictive diagnostic capability for coronary artery disease by offering non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans. This goes beyond automated measurements to aid in personalized diagnosis and treatment planning, backed by multiple peer-reviewed clinical studies.

Pricing & Value

Tie

Both tools have opaque pricing models, requiring direct contact with the vendor for custom quotes or details. Without specific pricing information or publicly available data on cost-effectiveness, it is impossible to conduct a meaningful comparison of their value propositions.

Enterprise Readiness

Cleerly ISCHEMIA

Cleerly ISCHEMIA explicitly states that it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, which are critical requirements for healthcare enterprises handling Protected Health Information. Libby Echo:Prio, in contrast, explicitly states 'no' for both BAA and HIPAA compliance, making it unsuitable for most regulated healthcare environments.

Innovation

Cleerly ISCHEMIA

Cleerly ISCHEMIA demonstrates higher innovation by offering non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA. These capabilities provide a more advanced and potentially transformative approach to diagnosing and managing coronary artery disease, moving beyond traditional anatomical assessment.

Support & Docs

Cleerly ISCHEMIA

Cleerly provides more specific information regarding its client support, including dedicated hours (Monday through Friday, 10 am ET to 6 pm ET) and clear channels for existing users to request technical support. Dyad Medical's support information for Libby Echo:Prio is more general, primarily offering email contacts without detailing specific support services or public documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Cleerly ISCHEMIA Libby Echo:Prio
Name Cleerly ISCHEMIA Libby Echo:Prio
Company Cleerly Dyad Medical
Description Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. Libby Echo:Prio by Dyad Medical is an FDA-cleared, cloud-based AI platform for fast, data-driven echocardiogram analysis, providing decision support and automated cardiac measurements for clinicians.
Primary Imaging Modality CCTA scans Echocardiogram
Key Features (Selected) AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination AI-powered cardiac image analysis, Cloud-based platform for remote access from any device, Fast, data-driven echocardiogram image analysis

Videos

Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Libby Echo:Prio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Cleerly ISCHEMIA is an AI tool that analyzes CCTA (Coronary Computed Tomography Angiography) scans to assess the likelihood of coronary artery ischemia, characterize plaque, and evaluate stenosis severity. In contrast, Libby Echo:Prio by Dyad Medical is designed for fast, data-driven analysis of echocardiogram images to provide automated cardiac measurements and decision support for cardiac function quantification.
Cleerly ISCHEMIA focuses on non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood determination, coronary plaque characterization (volume, type, location), and stenosis severity assessment from CCTA scans. Libby Echo:Prio provides AI-powered cardiac image analysis, automated estimation of cardiac measurements, and decision-making support for cardiac function quantification from echocardiograms, offering an immediately-available second opinion.
Cleerly ISCHEMIA offers integration with PowerScribe via an API. Libby Echo:Prio is designed to be embedded in existing clinical workflows.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.